Background Allergen specific immunotherapy has long been a controversial treatment for
asthma. Although beneficial effects upon clinically relevant outcomes have been
demonstrated in randomised controlled trials, there remains a risk of severe and sometimes
fatal anaphylaxis. The recommendations of professional bodies have ranged from cautious
acceptance to outright dismissal. With increasing interest in new allergen preparations and
methods of delivery, we updated the systematic review of allergen specific immunotherapy …